TWiV reviews Michael Worobey’s dissection of the early COVID-19 cases in Wuhan, and the discovery that herpesviruses assimilate cellular kinesin to produce motorized virus particles. Click arrow to playDownload TWiV 833 (77 MB .mp3, 128 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv
In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Click arrow to playDownload TWiV 831 (20 MB .mp3, …
TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin Read More »
TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitrowould not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in variants of concern, in the …
A TWiV duo reviews how SARS-CoV-2 attacks the olfactory mucosa but spares the olfactory bulb, vaccination with BNT162b2 induces virus-specific stem cell memory T cells, and development of an oral protease inhibitor for the treatment of COVID-19. Click arrow to playDownload TWiV 829 (67 MB .mp3, 112 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv
In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death. Show notes at microbe.tv/twiv
Multiple vaccines have been developed that have made substantial contributions to controlling the COVID-19 pandemic, but where are the antivirals? Only repurposed drugs have been used and not with much success. That situation seems about to change with the authorization of drugs that target the RNA polymerase (Molnupiravir) and a viral protease (Paxlovid). Molnupiravir is …
